A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

PURPOSE: On the basis of preclinical evidence of epigenetic contribution to sensitivity and resistance to immune checkpoint inhibitors (ICI), we hypothesized that guadecitabine (hypomethylating agent) and atezolizumab [anti–programmed cell death ligand 1 (PD-L1)] together would potentiate a clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, H. Josh, Hostetter, Galen, Macfarlane, Alexander W., Madaj, Zachary, Ross, Eric A., Hinoue, Toshinori, Kulchycki, Justin R., Burgos, Ryan S., Tafseer, Mahvish, Alpaugh, R. Katherine, Schwebel, Candice L., Kokate, Rutika, Geynisman, Daniel M., Zibelman, Matthew R., Ghatalia, Pooja, Nichols, Peter W., Chung, Woonbok, Madzo, Jozef, Hahn, Noah M., Quinn, David I., Issa, Jean-Pierre J., Topper, Michael J., Baylin, Stephen B., Shen, Hui, Campbell, Kerry S., Jones, Peter A., Plimack, Elizabeth R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233355/
https://www.ncbi.nlm.nih.gov/pubmed/36928921
http://dx.doi.org/10.1158/1078-0432.CCR-22-3642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233355/
https://www.ncbi.nlm.nih.gov/pubmed/36928921
http://dx.doi.org/10.1158/1078-0432.CCR-22-3642

Ejemplares similares